Why the study?
The clinical utility of endogenous serum neuregulin-1β in predicting left ventricular ejection fraction trajectory and survival in heart failure patients with systolic dysfunction is unclear.
Cohort (n=248)
No
Neuregulin-1β should not guide HF prognostication now; leaves open its association with LVEF trajectory.
CONTEXT: Improved left ventricular ejection fraction (LVEF) following administration of recombinant human Neuregulin-1β (NRG), epidermal growth factor (EGF) involved in cardiomyocyte repair/survival, has been observed in patients with systolic heart failure (HF). METHODS: Serum NRG was measured by ELISA in 248 patients with NYHA class I-IV HF. RESULTS: NRG exhibited a marginally significant effect on LVEF trajectory over 11 months (p = 0.07). There is no apparent level of NRG that predicts improved survival. CONCLUSIONS: There is a potential relationship between serum NRG and improved LVEF, indicating the need to investigate the utility of NRG in predicting HF outcomes, including LVEF maintenance.
No takes yet. Share an insight, caveat, or question.
Miao et al. (2018) conducted a cohort in Heart failure and left ventricular systolic dysfunction (ischemic or non-ischemic cardiomyopathy) (n=248). Endogenous serum neuregulin-1β (NRG) vs. Lower levels of endogenous serum neuregulin-1β was evaluated on Risk of death, cardiac transplantation, and LVAD implantation (transplant and advanced therapy-free survival) (HR 0.95 per 10-unit increase, p=0.3).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: